Previous investigators have found that cyclin CDK1, CCNB1 and CCNA2 are commonly overexpressed in TNBC and correlated with worse OS in breast cancer, so they could act as novel biomarkers for TNBC treatment [48]. This evidence concerns the gene CDK1 and breast carcinoma.